CD274 and non-small cell lung carcinoma: In the GESTONE-302 trial, which investigated the PD-L1 inhibitor sugemalimab in combination with platinum-based chemotherapy (S+P) in NSCLC, sugemalimab combined with chemotherapy improved PFS compared with placebo combined with chemotherapy (median PFS:9.0 months vs 4.9 months), with a more prominent benefit, especially in the sq-NSCLC subgroup.